Table 1.
Prevalent patients with S/V prescriptions.
| Drug(s) | 2016 |
2017 |
2018 |
2019 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | |
| S/V total (% of S/V total) | 5260 (100%) | 14,521 (100%) | 21,181 (100%) | 27,142 (100%) | 33,722 (100%) | 40,489 (100%) | 47,034 (100%) | 54,703 (100%) | 63,632 (100%) | 72,704 (100%) | 81,644 (100%) | 92,798 (100%) | 107,069 (100%) | 121,044 (100%) | 134,080 (100%) | 149,169 (100%) |
| S/V alone (% of S/V total) | 5231 (99.4%) | 14,366 (98.9%) | 20,905 (98.7%) | 26,747 (98.5%) | 33,164 (98.3%) | 39,621 (97.9%) | 45,811 (97.4%) | 53,148 (97.2%) | 61,586 (96.8%) | 70,129 (96.5%) | 78,501 (96.2%) | 88,926 (95.8%) | 102,343 (95.6%) | 115,240 (95.2%) | 127,190 (94.9%) | 140,347 (94.1%) |
| S/V + SGLT2i (% of S/V total) | 29 (0.6%) | 156 (1.1%) | 276 (1.3%) | 395 (1.5%) | 558 (1.7%) | 868 (2.1%) | 1223 (2.6%) | 1556 (2.8%) | 2047 (3.2%) | 2576 (3.5%) | 3143 (3.8%) | 3872 (4.2%) | 4726 (4.4%) | 5804 (4.8%) | 6890 (5.1%) | 8822 (5.9%) |
| Drug(s) | 2020 |
2021 |
2022 |
2023 |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | Q3 | Q4 | Q1 | Q2 | |
| S/V total (% of S/V total) | 165,676 (100%) | 174,480 (100%) | 184,947 (100%) | 195,261 (100%) | 207,290 (100%) | 219,762 (100%) | 235,367 (100%) | 252,061 (100%) | 270,326 (100%) | 286,160 (100%) | 301,287 (100%) | 318,595 (100%) | 337,463 (100%) | 351,262 (100%) |
| S/V alone (% of S/V total) | 154,620 (93.3%) | 161,763 (92.7%) | 170,448 (92.2%) | 177,760 (91.0%) | 184,194 (88.9%) | 188,633 (85.8%) | 192,310 (81.7%) | 186,971 (74.2%) | 182,817 (67.6%) | 175,685 (61.4%) | 170,785 (56.7%) | 166,561 (52.3%) | 163,538 (48.5%) | 158,833 (45.2%) |
| S/V + SGLT2i (% of S/V total) | 11,056 (6.7%) | 12,717 (7.3%) | 14,500 (7.8%) | 17,501 (9.0%) | 23,096 (11.1%) | 31,128 (14.2%) | 43,057 (18.3%) | 65,090 (25.8%) | 87,509 (32.4%) | 110,476 (38.6%) | 130,502 (43.3%) | 152,035 (47.7%) | 173,925 (51.5%) | 192,429 (54.8%) |
S/V = sacubitril/valsartan, SGLT2i = sodium–glucose co-transporter 2 inhibitor.